XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue
 3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The Company recorded the following revenues (in thousands):
Three Months Ended March 31,
20232022
ORLADEYO:
U.S.$60,849 $43,935 
Outside of U.S.7,565 5,769 
Total ORLADEYO68,414 49,704 
Other revenues364 219 
Total revenues$68,778 $49,923 
ORLADEYO revenues represent total revenues from product sales, collaborative revenues and royalties. Other revenues primarily relate to the Company’s galidesivir development contracts with BARDA/HHS and NIAID/HHS and product sales and royalties for peramivir injection (RAPIVAB/RAPIACTA/PERAMIFLU).